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Background: Mucinous carcinomas from different organs are morphologically similar and might share similarities at
the molecular and biochemical levels that may illuminate their pathogenesis and influence management. The factors
involved in the pathogenesis of mucinous carcinomas remain unknown; which is likely one contributor to the current
dearth of biomarkers for detection. Because zinc changes are implicated in some cancers e.g., prostate; we assessed the
possibility of a similar role in mucinous carcinomas.
Methods: The goal of the current work is to study the expression of hZip1 by immunohistochemistry in mucinous
carcinomas as compared with non-neoplastic epithelia and conventional carcinomas. Tissue microarray slides containing
mucinous carcinomas of the ovary (n = 35), colon (n = 51), stomach (n = 32) and lung (n = 21) were used.
Results: hZip1 showed persistent low expression in mucinous compared to ovarian serous carcinomas and normal
tissue (P < 0.05), colonic adenocarcinoma and normal mucosa (P < 0.001), and gastric adenocarcinoma and normal
epithelium (P < 0.05). hZip1 also showed low expression in pulmonary mucinous carcinomas.
Conclusions: hZip1 is consistently decreased in mucinous carcinomas from a variety of organs. Despite the fact that
these preliminary findings are unlikely to be of much diagnostic significance, these findings suggest that hZip1 plays
a fundamental role in the carcinogenesis of mucinous tumors.
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Clinical studies and experimental evidence have estab-
lished that zinc levels are consistently decreased in pros-
tate adenocarcinoma as compared to normal prostate
glands. The Zip1 zinc uptake transporter, in addition to
other members of the zinc transporter genes, is respon-
sible for the uptake and accumulation of zinc from the
circulation in the normal glands against the concentration
gradient. The malignant prostatic glands exhibit a down
regulation of Zip1, normally a ubiquitously expressed
protein, expression that will eliminate the uptake and
accumulation of zinc intracellularly [1–4].
In contrast to the aforementioned role of zinc in the
prostate, the role of hZip1 expression in adenocarcin-
omas of other organs has not previously been compre-
hensively examined. No such conclusive background* Correspondence: mokhtar.desouki@vanderbilt.edu
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creativecommons.org/publicdomain/zero/1.0/exists for epithelial ovarian cancer for example which is
considered one of the least understood of all major
human malignancies [5]. Identification of the most im-
portant initial alterations in ovarian cancer may facili-
tate the development of better methods for early
diagnosis, through the discovery of epithelial ovarian
cancer biomarkers, and for the development of more
optimal therapeutic approaches that target key molecu-
lar pathways [6].
There is evidence that relates zinc as a potential tumor
suppressor agent and ZIP1 transporter as a tumor sup-
pressor gene in some epithelial ovarian cancers. Lightman
et al. showed a highly significant decrease in the zinc
concentration of malignant ovarian tissue as compared to
their non-neoplastic counterparts [7]. Bae et al. showed
that zinc treatment of OVCAR-3 cells exerts tumor sup-
pressor effects with increased apoptosis [8]. The OVCAR-
3 is a human epithelial ovarian cancer cell line which was
established from the malignant ascites of a patient with
poorly differentiated “papillary adenocarcinoma” of thearticle distributed under the terms of the Creative Commons Attribution License
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blood and scalp-hair zinc levels with an increase in the in-
cidence of ovarian cancer has been reported [7, 10]. These
preliminary data make it reasonable to expect that there is
a difference in the zinc levels between malignant and non-
malignant cells which may be related to alteration of the
zinc uptake transporter; presumably Zip1.
In the current classifications of ovarian neoplasms,
mucinous tumors are classified as surface epithelial
tumors. Primary mucinous tumors of the ovary are
classified into benign, borderline, or malignant categor-
ies depending on their histopathologic features. The
neoplastic cells may be of gastrointestinal type, endo-
cervical type, or mixtures of both cell types that exist
in the seromucinous tumors [11] . Primary invasive
mucinous carcinomas of the ovary are very uncommon,
accounting for only 3-10 % of all ovarian epithelial tu-
mors, and metastatic tumors, most commonly from the
gastrointestinal tract (GIT), are more common [12, 13].
Therefore, the possibility that a mucinous tumor in the
ovary is metastatic rather than primary ovarian carcinoma
always must be entertained. Common primary sites are
GIT, especially the large intestine [14], appendix [15, 16],
and pancreas [17] and less commonly from stomach [18].
Endocervical adenocarcinomas occasionally spread to the
ovary [19].
We hypothesized that mucinous carcinomas, irre-
spective of different organ site, might share similarities
at the molecular and biochemical levels, which are
manifested by similar morphology at different anatomical
sites. The anatomical site obviously will dictate the surgi-
cal approach; however, the molecular and biochemical
characteristics might be more useful in the development
and composition of adjuvant treatment protocols.
In this report, we show, for the first time, a consistent
pattern of low expression of the hZip1 protein in mu-
cinous carcinomas from different organs, including the
ovary, colon, stomach and lung. The evidence pre-
sented herein indirectly supports the likelihood that
ZIP1 gene is an essential step in the development of
mucinous neoplasms.Results
Low expression of hZip1 in ovarian mucinous carcinomas
versus high expression in ovarian serous carcinomas
The average age of patients with ovarian carcinomas was
51.4 (range of 22–81) years. Tissue microarray (TMA)
comprised of 17 normal ovarian tissue, all of which were
strongly (3+) positive for hZip1. Sixty percent (21/35) of
mucinous carcinomas were negative (0) to weak (1+)
positive for hZip1 (Fig. 1a). In contrast, hZip1 expression
was moderately (2+) to strongly (3+) positive in 91 %
(138/152) of serous carcinomas (Fig. 1b). The expressionof hZip1 was significantly lower in ovarian mucinous
carcinomas as compared to serous carcinoma (1.3 versus
2.6; P < 0.001) and normal ovarian tissue (P = 0.015)
(Fig. 1c).
There was a statistically significant lower expression of
hZip1 in low grade serous compared to high grade serous
carcinomas (P < 0.05). Also, there was a lower expression
of hZip1 in low grade compared to high grade ovarian
mucinous carcinomas (P = 0.6). There was no association
between clinical stage and hZip1 IHC scores.Low expression of hZip1 in mucinous carcinomas versus
high expression in conventional adenocarcinoma of the
colon
The average age of patients with colonic carcinomas was
57.4 (range of 20–90) years. TMA comprised of 12
normal colonic tissue of which 83 % (10/12) were mod-
erately (2+) to strongly (3+) positive for hZip1. Fifty-five
percent (28/51) of mucinous carcinomas were negative
(0) to weak (1+) positive for hZip1 (Fig. 1d). In contrast,
hZip1 expression was moderately (2+) to strongly (3+)
positive in 96 % of conventional colonic adenocarcinoma
(124/129) cases (Fig. 1e). The mean expression of hZip1
was significantly lower in colonic mucinous carcinomas
(1.7) as compared to colonic conventional adenocarcin-
omas (2.8) and normal colonic mucosa (2.2) (P < 0.001)
(Fig. 1f ).
hZip1 expression was decreased as a function of increas-
ing grade in both mucinous and non-mucinous tumors of
the colon with no statistically significant difference. There
was no association between clinical stage and hZip1 IHC
scores.Low expression of hZip1 in mucinous carcinomas versus
high expression in conventional adenocarcinomas of the
stomach
The average age of patients with gastric carcinomas was
56 (range of 22–78) years. TMA comprised of 5 normal
gastric epithelium all of which were strongly (3+) positive
for hZip1. Twenty-two percent (7/32) of mucinous carcin-
omas were negative (0) to weak (1+) positive for hZip1
(Fig. 1g). In contrast, all conventional adenocarcinoma
cases (n = 4) were strongly (3+) positive for hZip1 (Fig. 1h).
The expression of hZip1 was significantly lower in gastric
mucinous carcinomas as compared to conventional gastric
adenocarcinoma (2.2 versus 3; P < 0.05) and normal gastric
epithelium (P = 0.027) (Fig. 1i).
The mean score of hZip1 was significantly lower in high
grade mucinous carcinomas of the stomach as compared
to their low grade counterparts (1.9 vs. 2.7, p < 0.01).
There was no association between clinical stage and hZip1
IHC scores.
Fig. 1 (See legend on next page.)
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Fig. 1 hZip1 expression in mucinous and non-mucinous carcinomas of the ovary, colon, stomach and lung. IHC analysis was performed on tissue
microarray slides comprised of 35 ovarian mucinous carcinomas, 152 ovarian serous carcinomas, 51 colonic mucinous carcinomas, 129 conventional
colonic adenocarcinomas, 31 gastric mucinous carcinomas, 4 conventional gastric adenocarcinomas and 21 pulmonary mucinous carcinomas.
a Representative negative ovarian mucinous carcinoma compared to b strongly positive serous carcinoma case for hZip1 protein. c Diagram
showing the average hZip1 IHC scores in normal ovarian, mucinous and serous carcinomas. d Representative weak positive colonic mucinous
carcinoma compared to e strongly positive conventional colonic adenocarcinoma case for hZip1 protein. f Diagram showing the average hZip1 IHC
scores in normal colonic epithelium, mucinous and conventional colonic adenocarcinomas. g Representative negative gastric mucinous carcinoma
compared to h strongly positive conventional gastric adenocarcinoma case for hZip1 protein. i Diagram showing the average hZip1 IHC scores in
normal gastric mucosa, mucinous and conventional gastric adenocarcinomas. j Representative weak and k strong positive pulmonary mucinous
carcinoma cases for hZip1 protein. ZIP1 protein was visualized using DAB with hematoxylin counterstain. Arrows showed the negative/weak positive
mucinous carcinoma cells. * There is statistically significant difference
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The average age of patients with pulmonary mucinous
carcinomas was 55.1 (range of 38–71) years. TMA com-
prised of 21 pulmonary mucinous carcinomas, of which
1, 3, 4 and 13 cases were negative (0), 1+, 2+, and 3+
positive for hZip1 protein expression, respectively with a
mean score of 2.4. Normal lung epithelium in adjacent
sections strongly (3+) expresses hZip1 (Fig. 1j and k).
There was no association between clinical stage and
hZip1 IHC scores.
Table 1 summarizes the results of hZip1 protein ex-
pression in normal tissue, mucinous and non-mucinous
carcinomas of the ovary, colon, stomach and lung.
Discussion
As a general rule, mucinous carcinomas represent a
small fraction of neoplasms in different organs with
about 3-10 % among ovarian neoplasms, 7 % of all colo-
rectal cancers, 1.5 % of gastric carcinomas, and veryTable 1 hZip1 expression in normal, mucinous and non-mucinous c




Mucinous carcinomas 15 (43 %) 6 (17 %)
Serous carcinomas 1 (0.7 %) 13 (9 %)
Colon
Normal 0 2 (17 %)
Mucinous carcinomas 3 (6 %) 25 (49 %)
Adenocarcinomas 1 (1 %) 4 (3 %)
Stomach
Normal 0 0




Mucinous carcinomas 1 (5 %) 3 (14 %)rarely in the lung [12, 20]. Compared with conventional
adenocarcinomas, mucinous tumors tend to be associ-
ated with young age, advanced tumor stage, and distinct
molecular patterns, such as microsatellite instability and
mutations of the BRAF and KRAS genes [21, 22].
Differentiation of primary ovarian mucinous carcinoma
from metastases of other organs mostly appendix and
colorectum can be challenging [13, 23]. This differenti-
ation is pivotal and of clinical significance given that treat-
ment protocols tend to be tailored to each organ site. For
example platinum-based taxane agents are used in the
treatment of primary ovarian carcinomas in contrast to
fluorouracil which is the main chemotherapeutic agent
used for metastatic carcinoma at the ovary originating
from the colorectum [24, 25].
For a tumor to be considered mucinous carcinoma
rather than a conventional adenocarcinoma depends on
organ site and classification systems. Ovarian mucinous
carcinomas show conspicuous amounts of intracellular
mucin in more than 90 % of tumor cells [11]. In contrast,arcinomas of the ovary, colon, stomach and lung
Total
2+ 3+
0 17 (100 %) 17
3 (9 %) 11 (31 %) 35
32 (21 %) 106 (70 %) 152
6 (50 %) 4 (33 %) 12
7 (14 %) 16 (31 %) 51
15 (12 %) 109 (84 %) 129
0 5 (100 %) 5
12 (37 %) 13 (41 %) 32
0 4 (100 %) 4
0 21 (100 %) 21
4 (19 %) 13 (62 %) 21
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of the tumor’s volume is composed of extracellular mucin
[26]. Mucinous carcinomas are distinct from conventional
and signet ring carcinomas in different organs with spe-
cific molecular alterations and clinical outcomes [25].
Common features between ovarian and colorectal mucin-
ous carcinomas include higher prevalence at younger age
and larger tumor size at presentation. In contrast, a
higher proportion of ovarian mucinous carcinomas
compared with serous carcinomas are diagnosed at a
low stage, while colorectal mucinous carcinomas seem
equally likely as non-mucinous carcinomas to present
at a low stage [23, 27, 28].
More than 2 decades ago, Lightman et al. [7] reported
low serum and tumor tissue zinc in patients with “malig-
nant ovarian tumors”. However, in this publication, no
mention of which kind of ovarian tumors were included
in the study and not much clinical information was pro-
vided [7]. Relatively more recently, Bae et al. [8] reported
that treatment of OVCAR-3 (malignant ovarian cell line)
and NOSE (normal ovarian cell line) with zinc–citrate
compound lead to induced zinc accumulation more in
the former cell line than the latter. This resulted in a de-
crease in cell number and activity of M-aconitase in
OVCAR-3 with increased apoptosis. The authors con-
cluded that exposure to high concentration of zinc pre-
vents the proliferation of OVCAR-3 cells [8]. The
OVCAR-3 cell line used by Bae et al. is a human epithe-
lial ovarian cancer cell line which was established from
the malignant ascites of a patient with poorly differenti-
ated “papillary adenocarcinoma” rather than mucinous
carcinoma of the ovary [8, 9]. More mechanistic studies
preferably with mucinous ovarian carcinoma cell lines e.g.,
RMUG-L, RMUG-S, MN-1, OMC-1 and MCAS [29] are
recommended to further explore the role of zinc and zinc
transporters in the pathogenesis and at least theoretically,
influence management of mucinous carcinomas.
We and others conclusively established that zinc levels
and hZip1 transporter are significantly decreased in pros-
tate adenocarcinomas. The background and supporting
evidence are fully and extensively presented in several
reviews and reports [1–4]. This encouraged us to extend
the study in the challenging mucinous carcinomas in
different organs and to compare the hZip1 expression in
mucinous versus non mucinous carcinomas in some of
these organs.
Our novel finding in this report is that hZip1 showed
consistently low expression in mucinous carcinomas of
the ovary, colon, stomach and lung with no association
between clinical stage and hZip1 scores in any of the
mucinous tumors. Interestingly, we identified low ex-
pression of hZip1 in mucinous carcinomas versus non
mucinous ones in three organs we performed the com-
parison in, namely; ovary, colon and stomach.Specifically, hZip1 is strongly expressed in all cases of
normal ovarian tissue and was moderately to strongly
positive in 91 % of serous carcinomas. In contrast, 60 %
of ovarian mucinous carcinomas were negative to weak
positive for hZip1 expression. The second interesting
finding is that there was a statistically significant lower
expression of hZip1 in low grade ovarian serous com-
pared to high grade serous carcinoma. Although it was
not statistically significant, still hZip1 expression was
lower in low grade compared to high grade mucinous
carcinomas. These observations may indicate that the
higher grade ovarian tumors may acquire different
mechanisms to accumulate more zinc by switching off
the inhibitory mechanisms which down express the zinc
transporter hZIP1 gene, or perhaps other members of
the zinc transporter gene family.
The scenario was the same in colonic and gastric
carcinomas with low expression of hZip1 in mucinous
carcinoma versus high expression in conventional adeno-
carcinomas in those two organs. In the colon and stom-
ach, 55 % and 22 % of mucinous carcinomas were
negative to weakly positive for hZip1, respectively. In
contrast, hZip1 expression was moderately to strongly
positive in 96 % and 100 % of conventional adenocarcin-
omas, respectively in the colon and stomach. The number
of conventional gastric adenocarcinomas included in the
TMA was small (n = 45). In contrast to ovarian carcin-
omas, hZip1 expression was decreased as a function of
increasing grade in both mucinous and non-mucinous
tumors of the colon and stomach. This observation may
point to different mechanisms involved in tumor progres-
sion regarding regulation of zinc concentration which
need more mechanistic studies. In the lung, we also identi-
fied low expression of hZip1 in pulmonary mucinous
carcinomas. Unfortunately, and due to un-availability of
conventional lung adenocarcinoma TMA slides, we did
not compare the expression of hZip1 in mucinous and
conventional pulmonary carcinomas.Conclusions
hZip1 expression appears to be consistently decreased in
mucinous carcinomas from a variety of organs relative
to non-neoplastic tissues in those organs. However,
hZip1 is also decreased as a function of increasing grade
in both mucinous and non-mucinous tumors in the
colon and stomach. These findings suggest that hZip1
plays a fundamental role in the carcinogenesis of some
organs that is particularly accentuated in mucinous tu-
mors. Additional studies are required to precisely define
the nature of this role. However, practically, there is little
value in low expression of hZip1 for differential diagnosis
of mucinous carcinomas.
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Tissue microarrays (TMAs)
All procedures were performed in compliance with rele-
vant laws and institutional guidelines with approval of
institutional review board. TMA slides purchased from
US Biomax (Rockville, MD) were used in the present
study. Ovary TMA slide comprised of 35, 152, 11 and 6
interpretable mucinous carcinomas, ovarian serous car-
cinomas, cancer adjacent normal tissue and normal
(non-malignant) tissues, respectively in a single tissue
core per case. It is not known if the mucinous carcin-
omas included in the TMA of the ovarian tumors are
of primary ovarian origin or metastatic tumors. Colon
TMA slide comprised of 51, 129 and 12 interpretable
mucinous carcinomas, conventional adenocarcinomas
and normal tissue, respectively in a single tissue core
per case. Stomach TMA slide comprised of 32 inter-
pretable mucinous carcinomas, 4 conventional adeno-
carcinomas and 3 cases of non-malignant normal and 2
tumor adjacent normal gastric tissue in duplicated
cores per case. Lung TMA slide comprised of 21 inter-
pretable mucinous carcinomas in a single tissue core
per case.Immunohistochemistry (IHC)
hZip1 protein expression was determined by IHC using
an anti-hZip1 antibody by standard protocol [1, 4].
Briefly, the TMA slides were deparaffinized in xylene
and rehydrated by incubation in decreasing concentra-
tions of ethanol. Antigen retrieval was done by heating
in 10 mM Tris-EDTA (10 mM Tris base, 1 mM EDTA,,
0.05 % tween 20, pH9.0) buffer at 98 °C for 20 min, IHC
staining was carried out by incubating slides in 5 %
BlokHen (AvasLabs, Tigard, Oregon) followed by incu-
bation overnight at 4 °C with hZip1 antibody in 5 %
BlokHen followed by incubation with Horseradish
peroxidase-labeled goat anti chicken IgY secondary anti-
body in a dilution of 1:200 (AvesLabs, Tigard, Oregon).
Color was developed with DAB+ chromogenic substrate
and hematoxylin was used as counterstain.
All sections were examined with an Olympus (BX53)
microscope. The pictures were processed with cellSens
Standard XV Image Processing software (Olympus Cor-
poration of the Americas, Center Valley, PA). IHC
scoring was performed by a board certified anatomic
pathologist (MMD). The appearance of membrane and
cytoplasmic associated hZip1 immuno-positivity of the
glandular epithelial cells was used for scoring as previ-
ously described [1, 4]. Tumor staining intensity was
semiquantitatively scored as negative (no staining), weak
(1+) (<10 %), moderate (2+) (10-50 %) and strong (3+)
(>50 %) positive depending on the percentage of positive
cells.Statistical analysis
The mean scores of hZip1 expression in different cat-
egories were analyzed by the Student’s t-Test. The IHC
scores were considered nominal to find out significance.
P ≤ 0.05 was considered significant.
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